{"id":762977,"date":"2023-06-12T08:12:48","date_gmt":"2023-06-12T12:12:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/"},"modified":"2023-06-12T08:12:48","modified_gmt":"2023-06-12T12:12:48","slug":"salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/","title":{"rendered":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress"},"content":{"rendered":"<h2>\nNew proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, June  12, 2023  (GLOBE NEWSWIRE) &#8212; <strong>Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX)<\/strong>, a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company\u2019s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023.<\/p>\n<p align=\"justify\">Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled \u201cA Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas\u201d and available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZYvlAWuSFxyc7Dc_YCD-VEEmsa2RHlCnePdmfxtfhunnQxyK3s6ZTL5cdmfrZRQDMnNJ2GiL22uSIAsCNezinw_u3lOidaBj_9KMDhpXgHKuMZibDmPyUbQL4rt2hxpNuho4LAse7mN-Kxae8hVNJA==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>, demonstrated:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Potent degradation of Ikaros and Aiolos (I\/A) in peripheral blood mononuclear cells (PBMC) within 2 hours of dosing, which increased in a dose- and time-dependent manner over 24 hours.<\/li>\n<li style=\"text-align:justify\">SP-3164 does not negatively impact PBMC at clinically relevant concentrations up to 96 hours post-treatment.<\/li>\n<li style=\"text-align:justify\">In addition to having direct antitumor effects, SP-3164 also induces an anticancer immunomodulatory effect as demonstrated through the induction of cytokine secretion in human T cells following treatment.<\/li>\n<\/ul>\n<p align=\"justify\">In addition, new quantitative proteomic data revealed that in Jeko-1 (lymphoma) cells, SP-3164 induces twice the degradation of target proteins I\/A at 1\/10<sup>th<\/sup> the dose of lenalidomide, providing further support for the development of SP-3164 in relapsed refractory non-Hodgkin lymphoma.<\/p>\n<p align=\"justify\">\u201cWe continue to advance our body of knowledge for SP-3164, with data generated to date demonstrating potent antitumor activity that supports our plans to file an Investigational New Drug application with the U.S. Food and Drug Administration in the coming weeks. We plan to begin a Phase 1 study in the second half of the year,\u201d said David Arthur, president and chief executive officer of Salarius. \u201cOur first therapeutic target is blood cancer, and we are excited to embark on a potential new treatment option for these patients.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About Salarius Pharmaceuticals<\/strong>\n      <\/p>\n<p align=\"justify\">Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius\u2019 product portfolio includes seclidemstat, Salarius\u2019 lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader that is being developed as a treatment for non-Hodgkin lymphoma.<\/p>\n<p align=\"justify\">Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration and is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing sarcoma. Salarius is also exploring seclidemstat\u2019s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1\/2 clinical study in hematologic cancers at MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is currently in IND-enabling studies and is anticipated to enter the clinic in 2023<strong>.<\/strong><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release and the referenced presentations contain \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release and the referenced presentations are forward-looking statements. These forward-looking statements may be identified by terms such as \u201cwill,\u201d \u201cbelieve,\u201d \u201cdeveloping,\u201d \u201cexpect,\u201d \u201cexcited,\u201d \u201cmay,\u201d \u201cprogress,\u201d \u201cpotential,\u201d \u201ccould,\u201d \u201clook forward,\u201d \u201cencouraging,\u201d \u201cmight,\u201d \u201cshould,\u201d and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the future of the company\u2019s Phase 1\/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas following the recently announced suspected unexpected severe adverse reaction (SUSAR) event and resulting partial clinical hold by the U.S. Food and Drug Administration (FDA); the advantages of protein degraders including the value of SP-3164 as a cancer treatment; the timing of clinical trials for SP-3164 and expected therapeutic options for SP-3164 and related effects and projected efficacy; the impact that the addition of new clinical sites will have on the development of Salarius\u2019 product candidates; the timing of Salarius\u2019 IND submissions to the FDA and subsequent timing for initiating clinical trials; interim data related to Salarius\u2019 clinical trials, including the timing of when such data is available and made public; Salarius\u2019 growth strategy; the value of seclidemstat as a treatment for Ewing sarcoma, Ewing-related sarcomas, and other cancers and its ability to improve the life of patients; expanding the scope of Salarius\u2019 research and focus to high unmet need patient populations; milestones of Salarius\u2019 current and future clinical trials, including the timing of data readouts. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: Salarius\u2019 ability to continue as a going concern; it may take considerable time and expense to resolve the partial clinical hold that has been placed on Salarius\u2019 Phase 1\/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas by the FDA, and no assurance can be given that the FDA will remove the partial clinical hold; Salarius\u2019 ability to resume enrollment in the clinical trial following its review of the available data surrounding the SUSAR; the sufficiency of Salarius\u2019 capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius\u2019 business operational needs and to achieve its business objectives and strategy; future clinical trial results and the impact of such results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; and other risks described in Salarius\u2019 filings with the\u202fSecurities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. The forward-looking statements contained in this press release and the referenced presentations speak only as of the date of this press release and the referenced presentations and are based on management\u2019s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p align=\"justify\">LHA Investor Relations<br \/>Kim Sutton Golodetz <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jrxDB6j102l1yKq8pOFFYgJyiI97XlvKbksiWfqTEhIdv1tpEq9RPR3ws-C9BzuTdLko0BZYxHoGLy3Tbx6O8BDTyY9J3u2H9_F_cGh44jw=\" rel=\"nofollow noopener\" target=\"_blank\">kgolodetz@lhai.com<\/a><br \/>212-838-3777<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTA0ZGNiODktNmI3ZC00ZWEzLTkwMzAtZWZkN2ExMDBiOWExLTEwMjgzNTA=\/tiny\/Salarius-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company\u2019s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023. Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled \u201cA Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas\u201d and available here, demonstrated: &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-762977","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company\u2019s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023. Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled \u201cA Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas\u201d and available here, demonstrated: &hellip; Continue reading &quot;Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-12T12:12:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress\",\"datePublished\":\"2023-06-12T12:12:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/\"},\"wordCount\":1133,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/\",\"name\":\"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\",\"datePublished\":\"2023-06-12T12:12:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","og_description":"New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company\u2019s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023. Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled \u201cA Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas\u201d and available here, demonstrated: &hellip; Continue reading \"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-12T12:12:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress","datePublished":"2023-06-12T12:12:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/"},"wordCount":1133,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/","name":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=","datePublished":"2023-06-12T12:12:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg1NTczNiM1NjM4NzkyIzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-presents-sp-3164-targeted-protein-degrader-preclinical-data-at-the-european-hematology-association-2023-hybrid-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=762977"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/762977\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=762977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=762977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=762977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}